Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GW813893 for VTE prophylaxis post-TKR
NCT00541320Phase 2Withdrawn
- Sponsor
- GSK
- Start
- Feb 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of GW-813893 in venous thromboembolism (VTE), sponsored by GSK. Primary endpoint: Incidence of death OR symptomatic or non-symptomatic blood clots in the legs OR symptomatic blood clots in the lungs at 7 days. Planned start Feb 2007; status: withdrawn.
02
Drugs
GW-813893
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT00541320.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00541320.